These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 15168376)

  • 1. Advanced glycation end products in kidney transplant patients: a putative role in the development of chronic renal transplant dysfunction.
    Hartog JW; Smit AJ; van Son WJ; Navis G; Gans RO; Wolffenbuttel BH; de Jong PE
    Am J Kidney Dis; 2004 Jun; 43(6):966-75. PubMed ID: 15168376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for chronic transplant dysfunction and cardiovascular disease are related to accumulation of advanced glycation end-products in renal transplant recipients.
    Hartog JW; de Vries AP; Bakker SJ; Graaff R; van Son WJ; van der Heide JJ; Gans RO; Wolffenbuttel BH; de Jong PE; Smit AJ
    Nephrol Dial Transplant; 2006 Aug; 21(8):2263-9. PubMed ID: 16597636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin resistance as putative cause of chronic renal transplant dysfunction.
    de Vries AP; Bakker SJ; van Son WJ; Homan van der Heide JJ; The TH; de Jong PE; Gans RO
    Am J Kidney Dis; 2003 Apr; 41(4):859-67. PubMed ID: 12666073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors of long-term graft loss in renal transplant recipients with chronic allograft dysfunction.
    Khalkhali HR; Ghafari A; Hajizadeh E; Kazemnejad A
    Exp Clin Transplant; 2010 Dec; 8(4):277-82. PubMed ID: 21143092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of total homocysteine, homocysteine metabolites and of advanced glycation end-products (AGEs) in patients after renal transplantation.
    Franke S; Müller A; Sommer M; Busch M; Kientsch-Engel R; Stein G
    Clin Nephrol; 2003 Feb; 59(2):88-97. PubMed ID: 12608551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease.
    Hartog JW; de Vries AP; Lutgers HL; Meerwaldt R; Huisman RM; van Son WJ; de Jong PE; Smit AJ
    Ann N Y Acad Sci; 2005 Jun; 1043():299-307. PubMed ID: 16037252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced glycation end products.
    Thomas MC
    Contrib Nephrol; 2011; 170():66-74. PubMed ID: 21659759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced glycation end products in the pathogenesis of chronic kidney disease.
    Rabbani N; Thornalley PJ
    Kidney Int; 2018 Apr; 93(4):803-813. PubMed ID: 29477239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Causes of late renal transplant dysfunction].
    Szabó A; Müller V
    Orv Hetil; 2002 Dec; 143(51):2811-9. PubMed ID: 12638307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AGE-RAGE interaction and oxidative stress in obesity-related renal dysfunction.
    Tomino Y; Hagiwara S; Gohda T
    Kidney Int; 2011 Jul; 80(2):133-5. PubMed ID: 21720304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced glycation end products (AGEs) estimated by skin autofluorescence are related with cardiovascular risk in renal transplant.
    Calviño J; Cigarran S; Gonzalez-Tabares L; Menendez N; Latorre J; Cillero S; Millan B; Cobelo C; Sanjurjo-Amado A; Quispe J; Garcia-Enriquez A; Carrero JJ
    PLoS One; 2018; 13(8):e0201118. PubMed ID: 30067789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced glycation end products and oxidative stress are increased in chronic allograft nephropathy.
    Raj DS; Lim G; Levi M; Qualls C; Jain SK
    Am J Kidney Dis; 2004 Jan; 43(1):154-60. PubMed ID: 14712439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenic role of advanced glycation end-products (AGEs): an overview.
    Weiss MF
    Perit Dial Int; 1999; 19 Suppl 2():S47-52. PubMed ID: 10406493
    [No Abstract]   [Full Text] [Related]  

  • 14. [Post-transplant nephropathy and arterial hypertension].
    Oko A; Idasiak-Piechocka I; Czekalski S
    Przegl Lek; 2001; 58(9):859-63. PubMed ID: 11868248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-transplant hypertension: a major risk factor for chronic progressive renal allograft dysfunction?
    Frei U; Schindler R; Wieters D; Grouven U; Brunkhorst R; Koch KM
    Nephrol Dial Transplant; 1995; 10(7):1206-11. PubMed ID: 7478125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndrome.
    Willemsen S; Hartog JW; Heiner-Fokkema MR; van Veldhuisen DJ; Voors AA
    Heart Fail Rev; 2012 Mar; 17(2):221-8. PubMed ID: 21259070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonesterified fatty acids and development of graft failure in renal transplant recipients.
    Klooster A; Hofker HS; Navis G; Homan van der Heide JJ; Gans RO; van Goor H; Leuvenink HG; Bakker SJ
    Transplantation; 2013 Jun; 95(11):1383-9. PubMed ID: 23524974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal N(epsilon)-carboxymethyllysine deposition after kidney transplantation.
    Baumann M; Caron M; Schmaderer C; Schulte C; Viklicky O; von Weyhern CW; Lutz J; Heemann U
    Transplantation; 2008 Jul; 86(2):330-5. PubMed ID: 18645498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic damage in end-stage renal failure: potential involvement of advanced glycation end products and carbonyl stress.
    Stopper H; Schupp N; Bahner U; Sebekova K; Klassen A; Heidland A
    Semin Nephrol; 2004 Sep; 24(5):474-8. PubMed ID: 15490414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue advanced glycation end product deposition after kidney transplantation.
    Crowley LE; Johnson CP; McIntyre N; Fluck RJ; McIntyre CW; Taal MW; Leung JC
    Nephron Clin Pract; 2013; 124(1-2):54-9. PubMed ID: 24135496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.